drugset
Drugs / CodaVax-RSV
last change Jul 2026 re-read 3 minutes ago

CodaVax-RSV

Vaccine

Developed for
respiratory syncytial virus infectious disease
Investigated by
Codagenix, Inc

Trials 2

today NCT04919109 · Ph 1 NCT04295070 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04919109 Mar 2023 → Jun 2025 respiratory syncytial virus infectious disease Codagenix, Inc Terminated No outcome recorded Stop: Business
Phase 1 NCT04295070 Jul 2020 → Mar 2021 respiratory syncytial virus infectious disease Codagenix, Inc Completed Met primary

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2022-11-02 Codagenix, Inc Regulatory Codagenix Receives FDA Fast Track Designation for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV codagenix.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV).
2022-06-01 Codagenix, Inc Regulatory Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV codagenix.com ↗
With this FDA clearance, the company plans to initiate a Phase 1 study of vaccine safety and immunogenicity against RSV in healthy children aged six months to five years.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as CodaVax-RSV ClinicalTrials.gov intervention name — accepted as the source's own label NCT04295070 ↗
1

NCT04919109 ↗
Modality Vaccine “Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper” NCT04295070 ↗
Route Intranasal “delivered intranasally via dropper” NCT04295070 ↗